Evidence map›Paper›PMID 41648793›Full record

ArticleDigital health

Evaluation of symptom-management medications for predicting short-term survival in advanced cancer patients with machine learning.

Hua-Shui Hsu, Chia-Hung Kao, Shih-Sheng Chang, Kuo-Chen Wu, Po-Tsung Huang, Shen-Ju Tsai, Ya-Zhu Tang, Wen-Yuan Lin

Abstract read
In one paragraph

Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hua-Shui HsuDepartment of Family Medicine and Social Medicine, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.ORCID https://orcid.org/0009-0008-6132-4187
Chia-Hung KaoArtificial Intelligence Center, China Medical University Hospital, Taichung, Taiwan.
Shih-Sheng ChangArtificial Intelligence Center, China Medical University Hospital, Taichung, Taiwan.
Kuo-Chen WuArtificial Intelligence Center, China Medical University Hospital, Taichung, Taiwan.
Po-Tsung HuangDepartment of Family Medicine and Social Medicine, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Shen-Ju TsaiDepartment of Family Medicine and Social Medicine, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
Ya-Zhu TangDepartment of Nursing, China Medical University Hospital, Taichung, Taiwan.
Wen-Yuan LinDepartment of Family Medicine and Social Medicine, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Estimating the diverse symptoms of patients with advanced cancer is helpful for young physicians and medical teams in planning appropriate palliative care. We evaluated the use of medication, comorbidities, laboratory test results, and vital signs in hospitalized patients to predict death within 14 days. Methods: We retrospectively selected hospitalized patients with advanced cancer who were admitted to the hospice ward. We are using extreme gradient boosting (XGBoost) and a combination of random forest (RF) and XGBoost (RF-XGBoost) models to analyze sixteen comorbidities, eighteen types of medications, twenty-six laboratory tests, and six vital signs. Finally, SHapley Additive exPlanations (SHAP) analysis was employed to interpret the contribution of each feature to survival prediction. Results: Among the 2276 patients, 73% survived less than 14 days. The Area under the curve (AUC) of the XGBoost and RF-XGBoost models was 0.82 and 0.81 ( Conclusions: Our results suggest that the types of medications used by patients, especially stool softeners, antiemetics, and sedatives, are valuable in predicting survival beyond 14 days for hospitalized patients with advanced cancer. This result may assist young physicians and medical teams in developing appropriate palliative care plans for patients and their families.

Indexed as

advanced cancer patientsmachine learningMedicationsurvivalsymptom

Identifiers

PMID41648793
PMCPMC12868595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.